CSBR
Champions Oncology, Inc.6.73
-1.14-14.5%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
Key Stats
Market Cap
93.45MP/E (TTM)
39.59Basic EPS (TTM)
0.17Dividend Yield
0%Recent Filings
10-Q
Q3 FY2026 results
Champions Oncology posted Q3 FY2026 oncology revenue of $16.6M, down 2.8% y/y yet up 2.2% YTD to $45.6M, but swung to an operating loss of $0.3M from $4.5M profit while gross margin slipped to 46.7% from 61.2% on higher outsourced lab costs like radiolabeling. Operating expenses climbed across R&D, sales, and G&A from investments in data platforms and commercial expansion; net loss hit $0.3M or $(0.02) diluted EPS, consistent with 13.9M shares as options turned anti-dilutive. Cash fell to $7.1M after $2.5M operating outflow, no debt beyond minor leases. Bookings improved modestly. Cash covers needs through March 2027. Economic volatility threatens demand.
8-K
Q3 revenue dips, services surge
Champions Oncology posted Q3 fiscal 2026 total revenue of $16.6 million, down 2.8% year over year without last year's $4.5 million data license, yet study services soared 32% on backlog conversion. Adjusted EBITDA hit $574,000 amid outsourced radiolabeling costs over $2 million. Stays on track for full-year growth. Cash stands at $7.1 million, debt-free.
8-K
Q2 revenue up 11% to $15M
Champions Oncology posted Q2 revenue of $15M, up 11% year-over-year, with oncology services margin expanding to 52% from 45% on operational efficiencies. Adjusted EBITDA hit $843K despite higher R&D and sales investments for its data platform. Record service revenue underscores growth. On track for full-year revenue gains and positive adjusted EBITDA.
10-Q
Q2 FY2026 results
Champions Oncology posted Q2 FY2026 oncology revenue of $15.0M, up 11.5% y/y from $13.5M, while gross margin held at 51.7% despite higher R&D and G&A from data licensing and Corellia investments. Operating income slipped to $185K from $732K y/y, but Q2 turned profitable versus Q1's $527K loss (derived). YTD revenue rose 5.4% to $29.0M yet swung to a $342K operating loss on 49.5% R&D growth; net loss of $230K reflected anti-dilutive options in EPS math. Cash sits at $8.5M after $1.1M operating outflow, with no debt beyond minor leases. Lease terminated in Italy. Economic volatility shadows demand.
8-K
Annual meeting approves board, auditors
Champions Oncology's stockholders unanimously ratified EisnerAmper LLP as independent auditors for fiscal year 2026 at the October 16, 2025 annual meeting. All seven director nominees secured election with strong support, though David Sidransky faced notable withheld votes. The advisory vote on executive compensation passed overwhelmingly. Board continuity bolsters steady governance amid oncology research demands.
IPO
Employees
Sector
Industry
BZYR
Burzynski Research Institute, I
0.03-0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CRDF
Cardiff Oncology, Inc.
2.40-0.01
CTOR
Citius Oncology, Inc.
1.07+0.02
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
LADX
LadRx Corporation
0.11+0.00
NTHI
NeOnc Technologies Holdings, In
9.44-0.44
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00